View More Recent Stories
-
BioNTech (BNTX) PT Raised to $150 at BofA Securities
-
BioNTech (BNTX) PT Raised to $96 at Jefferies
-
Tempus AI (TEM) Announces Real World Data Collaboration with BioNTech (BNTX)
-
Pfizer (PFE) and BioNTech (BNTX Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
-
BioNTech SE (BNTX) Announces Lift of Partial Clinical Hold for BNT326/YL202
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX)
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
Pfizer (PFE) and BioNTech (BNTX) Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
-
BioNTech (BNTX) PT Lowered to $85 at TD Cowen
-
BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley
-
Midday movers: Apple, Nvidia, Intel, Coinbase and Moderna fall
-
BioNTech SE (BNTX) Misses Q2 EPS by 134c, reiterates guidance
-
BioNTech SE (BNTX) call put ratio 2.4 calls to 1 put with focus on September 82.50 calls
-
HSBC Upgrades BioNTech (BNTX) to Buy
-
BioNTech (BNTX) Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
-
Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
BMO Capital: 'BNT324 Granted Fast Track Designation, An Incremental Positive' for BioNTech (BNTX)
-
BioNTech SE (BNTX): FDA has placed partial clinical hold on multicenter, open-label, first-in-human Phase 1 clinical (NCT05653752) trial sponsored by MediLink
